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Background: Patients enrolled in clinical trials continue to have frequent contacts with primary 
care physicians because of comorbidities or toxicities. The aim of the present study was to 
analyze the information provided at different levels, when participants are included in clinical 
trials organized at a specialized care level. The purpose was to verify if informing the patient’s 
primary care physician is contemplated in the inclusion process.
Methods: The authors conducted a cross-sectional study that included the clinical trials 
approved in the last 2 years by the hospital’s Institutional Review Board. In addition, some of 
the participants in the included clinical trials were interviewed in order to check their knowledge 
of the type of research taking place.
Results: In total, 67 protocols and the accompanying informed consent documents were 
reviewed. Half of the reviewed protocols (48%) did not provide participants with an identifica-
tion card. Regarding the role of the primary care physician, 68.6% of clinical trials (46/67) had 
taken it into account in different ways. In only four trials, the method used to contact the primary 
care physician was documented. In total, 20 participants were interviewed. Only 3 (15%) knew 
the title of the study in which they were participating, 14 (70%) were aware of their illness and 
6 (30%) did not know how to answer any of these two questions. Almost all participants in the 
study knew the name of the physician who was the principal investigator in the trial.
Conclusion: Information given to health care practitioners, who are not directly involved 
in clinical trials conducted by specialized medical staff, is still scarce. In our clinical setting, 
patients participating in clinical trials have a low awareness of such studies.
Keywords: informed consent, clinical trials, family physician, wallet card
Introduction
Most medical patients are treated in the primary care settings, while most of the 
patients included in clinical trials are treated and monitored within the academic set-
ting.1,2 In contrast, in our clinical setting the majority of cancer patients are treated in 
specialized clinics and oncologists are responsible for the enrollment of these patients 
in clinical trials. However, all patients enrolled in clinical trials, including cancer 
patients, continue to have frequent contacts with primary care physicians because 
of comorbidities, toxicities or needs of additional information. This is why primary 
care physicians have to be aware of the enrollment of their patients in clinical trials. 
Moreover, good clinical practice (GCP) guidelines recommend that, when conduct-
ing a trial, the patient’s primary care physician should be informed about the subject’s 
enrollment in the study. This would only happen after obtaining the subjects consent 
to release this information. Clinical trial enrollment is a key information for any health 
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care professional, but especially for those who can prescribe 
drugs with a potential to interact with study medications or 
those who might care for the patient in emergency facilities.
Clinical investigators, and especially oncologists, need to 
communicate more effectively with primary care physicians 
if they are to expect their cooperation in referring potential 
subjects that could be considered for enrollment in a clinical 
trial. Furthermore, the primary care team is very well placed 
for monitoring how well patients are responding to cancer 
treatments. There needs to be a mechanism to help inform 
doctors about what clinical trials that are available to their 
patients and what are the selection criteria that are available 
for those trials in their catchment area.3,4 Means for obtain-
ing information regarding questionable methods for treating 
cancer should be more easily accessible.4
In particular, clinical research requires a multidisciplinary 
team, and a primary care physician must be part of that team. 
Ensuring the successful development and conduct of clinical 
trials in practice-based research networks (PBRN), requires 
a highly collaborative approach between academic research 
experts and PBRN teams.5 Trial participation is very often 
limited by the primary care physician’s lack of awareness 
of the available clinical trials for patients treated in their 
area of practice. According to a 2004 survey conducted by 
Taylor, the most common reason given by physicians when 
explaining nonparticipation in clinical trials was a lack of 
knowledge of their existence.6 Furthermore, primary care 
and specialized consultants who are not in partnership with 
research institutions might be even less aware of a patient’s 
eligibility for inclusion in a clinical trial.7 Physicians are 
the main channel for patient entry into a clinical trial and, 
therefore, their knowledge and endorsement of the trials is 
essential in the enrollment of subjects.8
The primary resources, useful in locating information 
about clinical trials, are the clinical trial registries available 
to patients and health care professionals.7 There are a number 
of registries that set different goals depending on the intended 
user. The most comprehensive public registry to date is 
ClinicalTrials.gov, since February 2000, where all entities 
conducting trials with experimental treatments are required 
to submit information. The specific information requested 
for registration with ClinicalTrials.gov was established by 
the National Library of Medicine of the US Department of 
Health and Human Services as a result of Section 113 of the 
FDA Modernization Act of 1997. However, public awareness 
of clinical research coming from other sources is increasing8,9 
and there is a need to overcome misconceptions regarding 
clinical trials.10,11
On another matter, recruitment methods are varied. The 
extended system for communicating clinical trial participa-
tion consists of a referral letter addressed to the clinicians 
asking them to recruit subjects from their own population of 
patients and to refer potential ones. Letters addressed to the 
treating clinician do not usually have to be approved by the 
Institutional Review Board (IRB); however, other recruit-
ment methods and means (letters, flyers, posters, etc.) used 
to contact potential subjects must be approved by the IRB. It 
is also advisable to include an IRB approved study summary 
and/or brochure(s) with this referral letter.
The aim of the present study was to analyze the informed 
consent of a series of clinical trials. The main objective was 
to confirm that making the primary care physicians aware 
of the inclusion of one of their patients in a trial is in the 
informed consent.
In addition, the authors checked for the existence of a 
personal patient card which identified the participants in the 
clinical trial; they also ascertained whether this document 
contained useful information for practitioners who are not 
included in the research team. The present research was 
promoted by the “Comite Ètic d’Investigació de l’Hospital 
Universitari Arnau de Vilanova” and approved by the same 
IRB. The participants interviewed provided written informed 
consent when included in the clinical trials that were analyzed.
Methods
The authors conducted a cross-sectional study that included 
the trial protocol (specifically the informed consent form) 
for clinical trials approved in the last 2 years by the hospital 
IRB. This documentation was reviewed and the following 
variables were calculated:
1. The proportion of clinical trials in which a personal iden-
tification card (ID) is provided to participants, and this 
is specified in the informed consent form. The ID must 
contain the title of the study, identification and contact 
details for the principal investigator (PI), and the most 
important safety considerations about the study.
2. The proportion of trials in which informed consent pro-
vides the option to inform the general practitioner about 
the participation in the clinical trial.
3. Among trials that specify the option to inform the patient’s 
general practitioner, the authors sought to identify who 
was in charge for this communication.
The authors also interviewed some of the participants in the 
included clinical trials to check their understanding of the research 
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well as their feelings related to trial participation. The complete 
text of the survey is provided in Figure S1. Once included in a 
clinical trial, participants would be referred to the clinical trial 
pharmacy service so that the experimental medication could be 
dispensed. It was at this point, during the dispensing visits in 
pharmacy, that the participants would be interviewed.
Results
In total, 67 protocols and the accompanying informed con-
sent documents were reviewed; the majority of studies were 
specialized in oncology (33/67; 49.25%) but other fields, such 
as cardiology or endocrinology, were also involved. Most of 
the trials were Phase II or III (63/67; 94%).
Clinical trial protocols and information 
for the general practitioner
As is displayed in Figure 1, nearly half of the reviewed 
protocols (48%) did not provide participants with an ID 
card. Among those who did provide an ID card, a significant 
proportion (37%) did not mention this card and its utility in 
the informed consent form. 
Regarding the role of the primary care physician, 68.6% 
of clinical trials (46/67) had considered this in different 
ways and did refer to it in the informed consent. In contrast, 
in 31.3% (21/67) of the protocols there was no reference at 
all. Among trials that mentioned the role of the primary care 
physician, the methods used to communicate the inclusion 
of the patient in the clinical trial are shown in Figure 2. In 
most cases, the informed consent stated that the patients 
were agreeing to allow medical staff involved in the study to 
contact their primary care physician. However, in only four 
trials the specific method used for that purpose was indicated, 
usually through an informative letter.
Participant interviews
This interview was proposed to 38 subjects, but only 20 
agreed to take part in it (6 men and 14 women). Only 3 (15%) 
knew the title of the study in which they were participating, 
14 (70%) were aware of their illness and 6 (30%) could not 
answer either of these two questions. However, nearly all 
the participants (18/20) could remember the name of the PI.
Regarding the ID card (informing about the participation 
in a clinical trial), only 3/20 (15%) participants declared that 
they had been provided with such identification at the begin-
ning of the study. When the interviewed subjects were asked 
about their awareness of the convenience of informing their 
primary care physician with regard to their participation in 
the study, half of them responded negatively. However, the 
majority of subjects (70%) pointed out that their primary 
care physician was aware of their inclusion in a clinical trial, 
mostly through personal communication with the PI through 
a letter or through a note in their electronic medical records. 
Nearly all the interviewed subjects (18/20) considered that 
their family physician should be informed of their inclusion 
in a clinical trial.
Finally, regarding the best way to inform primary care 
physicians, patients were asked to rate from 1 to 5, 5 being 
the highest score, the different methods that could be used. 
The results of the scores for this part of the survey are showed 
in Figure 3. It must be noted that the option “Through elec-
tronic medical records” obtained the best score (93 of the 
maximum 100 points).
Discussion
Our results confirm that there is a significant number of 
clinical trials that do not correctly communicate the fact 
that the patients are being included in such a trial to the 
family physician. There is a scarcity of published work on 
this matter, although much attention has been devoted to the 
informed consent and how to use it. Some IRBs include an 
ID participation card as part of the documentation required 
for the clinical trial to be accepted for review. GPC guide-
lines state that “all subjects participating in a clinical trial 
with an Advanced Therapy Investigational Medicinal Prod-
uct (ATIMP) should receive from the investigator an alert 
Figure 1 Provision of identification card to participants in the clinical trials.







Yes but no explanation
in the IC















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





card, … containing as minimum the name of the subject, the 
investigator contact number and information regarding the 
medical treatment received.”12
The lack of available basic information about the clinical 
trial characteristics, for instance the title and the PI contact 
information, can generate safety issues for patients.13,14 Most 
of the trials we have included in the survey recruit patients 
with a chronic illness (e.g., diabetes) or cancer. These patients 
could have acute exacerbations of their illness or experiment 
adverse effects that would need attention in emergency care 
facilities; without adequate information about what can be 
done and what interventions must be avoided, there is a risk 
of the attending medical staff making erroneous decisions, 
that at worst could result in fatalities and at best in the patient 
exclusion from the trial. In these cases, it is critical to have 
information about the adverse reactions that the experimental 
treatment can induce and how to manage them in order to 
avoid investing unnecessary efforts and valuable time into 
investigating the causes of the clinical manifestations that the 
patient presents with. The use of an ID card, which includes 
basic information about the trial, is the easiest and most 
effective way to provide such information. Although more 
than half of the protocols included in this study supplied par-
ticipants with an ID card, only a minority of the interviewed 
participants declared that they had received such a card at 
the beginning of the study.
Most of the clinical trial participants who were interviewed 
did consider that their family physician should be informed 
about their participation in a trial. Due to their frequent 
contacts with the primary care staff, participants saw this as 
necessary. As a whole, nearly 2 out of 3 protocols did consider 
informing the general practitioner and, in most cases, the 
responsibility of doing so relied on the PI. Unfortunately, in 
the present study, we could not verify whether this action was 
really performed. It must be noted that in some protocols the 
responsibility of informing the family physician is transferred 
to the participant. In the case of our IRB, this is not accepted 
since it is considered that the best way to transfer the informa-
tion is through direct communication between practitioners, 
either by using electronic medical records or personal letters. 
Moreover, our committee agrees not to inform the family 
doctor if the patient manifests explicitly against.
Our team has modeled these initiatives on those promoted 
by the clinical research nurses working for the Experimental 
Cancer Medicine Center Network; they care for patients 
participating in translational and early phase clinical trials 
across the Network.15 Some of the key ideas developed by 
this group of nurses are: 1) the wider use of patient wallet 
cards for clinical study ID and out-of-hours contact details, 
and 2) the use of patient electronic records to upload an alert 
notifying staff that the patient is taking part in a trial and to 
regularly update the research section.
As is acknowledged by most institutions, patients being 
admitted to a nontreating hospital – that is, not where the trial 
is being run – are still a barrier to best practice. Our center 
is working on a project to establish a formal procedure to 
inform general practitioners and emergency facilities about 
subjects’ participation in a clinical trial. This procedure will 
warrant confidentiality for the subject and the clinical trial 
sponsor, and electronic health records will be the main tool. 
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Nowadays, our health system’s electronic records allow health 
information to be shared between specialized and primary 
care. The proposal is to create an alert that triggers when a 
patient is included in a clinical trial; this warning will contain 
basic information about the trial.
Conclusion
Information directed to health care practitioners who are not 
involved in clinical trials conducted by specialized medical 
staff is still scarce and there is great variability in the methods 
used to transmit such information. Although the provision of 
patient wallet cards for clinical study ID is widespread, the 
use of such identification remains questionable. Fortunately, 
there is a significant majority of clinical trial participants 
who recognize that their family physicians are aware of their 
inclusion in a clinical trial.
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Name of the trial/disease: 
Clinical trial physician:
1. Related with your participation in the clinical trial, have you been given a clinical trial participation card?
  Yes / No / Don’t know/refused
2. Has been reported in the trial consent form that your general practitioner will be informed?  
  Yes / No / Don’t know/refused
3. Does your general practitioner know that you are participating in a clinical trial?
  Yes / No / Don’t know/refused
4. If your answer is Yes, how did your general practitioner get the information?
5. Do you think that your general practitioner must know that you are participating in a clinical trial?
  Yes / No
6. In your opinion, which is the best way to inform your general practitioner that you are involved in a clinical trial? (prefer-
ence order: 5 → first place, 1 → last place)
 That you or a relative deliver your general practitioner a letter received from the investigator.
 
That you or a relative send your primary health centre a letter provided from the investigator. 
 What would you prefer, an opened envelope or a closed one? (choose with a cross)
  Opened
  Closed 
 How would you prefer to deliver it, personally or by mail?
  Personally 
  By mail
 
That the clinical trial investigator informs to the general practitioner.
 
That the sponsor informs to the general practitioner.
 
That the general practitioner could find the information in the electronic medical history projected as an alarm.
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